Subscribe


OncoDefender launch

THIS week Everist Genomics
announced the worldwide
commercial availability of its new
genetic test to assess risk of
recurrence of both stage I/II colon
cancer and stage I rectal cancer
following surgery, OncoDefender.
See www.everistgenomics.com.